Thendor peptide

Thendor peptide is an investigational peptide-based therapeutic being developed by Thendor Therapeutics for the treatment of fibrosis. The drug is designed to target and rebalance fibrosis-associated cellular signaling pathways that become dysregulated during chronic disease. In fibrotic conditions, overactive pro-fibrotic signaling leads to the excessive accumulation of extracellular matrix and the formation of scar tissue, which ultimately impairs organ function. Thendor's technology aims to restore healthy tissue repair by modulating these signaling imbalances, thereby reducing pro-fibrotic signaling and preventing or reversing pathological scarring. The therapeutic is currently in the early stages of development, focusing on restoring the natural balance of tissue maintenance and repair.